DSM Biologics and Crucell Announce PER.C6 Licensing Deal With Sartorius Biotech GmbH

08-Jun-2007

Royal DSM N.V. and Crucell N.V. announced a non-exclusive PER.C6® research licensing deal with Goettingen, Germany-based Sartorius Biotech GmbH. Sartorius will use Crucell's key technology to evaluate monoclonal antibodies produced using PER.C6® cells for calibrating and testing equipment products useful in the manufacture and/or purification of recombinant monoclonal antibodies. Crucell and Sartorius further agreed to expand their PER.C6® collaboration by sharing technology and data on antibody production. Financial details were not disclosed.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous